CLOs on the Move

Bio-Techne

www.bio-techne.com

 
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne`s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.bio-techne.com
  • 614 McKinley Place NorthEast
    Minneapolis, MN USA 55413
  • Phone: 612.379.2956

Executives

Name Title Contact Details
Trevor Woodage
Assistant General Counsel, Intellectual Property Profile
Shane Bohnen
Associate General Counsel Profile
Shane Bohnen
Senior Vice President and General Counsel Profile
Brenda Furlow
General Counsel Profile
Brenda Furlow
Executive Vice President, General Counsel and Chief Sustainability and Compliance Officer Profile

Similar Companies

Agenta Biotechnologies

Agenta Biotechnologies is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ordaos Bio

Ordaos is a human-enabled, machine-driven drug design company.

Aqualung Therapeutics

Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension.

NexImmune

NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.